CompletedPhase 2NCT02501018
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lisata Therapeutics, Inc.
- Principal Investigator
- Kristen K Buck, MDLisata Therapeutics, Inc.
- Intervention
- CLBS12(biological)
- Enrollment
- 33 enrolled
- Eligibility
- 20-85 years · All sexes
- Timeline
- 2017 – 2022
Study locations (12)
- Asahikawa Medical University Hospital - 1-1-1 Higashi-2jou, Midorigaoka, Asahikawa-shi, Japan
- Fukuoka Sanno Hospital, Fukuoka, Japan
- Shonan Kamakura General Hospital, Kamakura, Japan
- Kobe City Medical Center General Hospital, Kobe, Japan
- Shinsuma General Hospital, Kobe, Japan
- Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
- Oita Oka Hospital, Ōita, Japan
- Nippon Medical School Hospital, Tokyo, Japan
- Keio University Hospital, Tokyo, Japan
- Toho University Medical Center Ohashi Hospital, Tokyo, Japan
- Tokyo Medical University Hospital, Tokyo, Japan
- Tokyo Women's Medical University, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02501018 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07215923A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy SmokersAntidote Therapeutics, Inc
- ENROLLING BY INVITATIONNCT07023965Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)Beijing Northland Biotech. Co., Ltd.
- RECRUITINGPHASE4NCT05854615Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's DiseaseCell Biopeutics Resources Sdn Bhd